Both ECC4703 and ECC0509 demonstrated best-in-class potential, with favorable safety and tolerability profiles, clear target engagement and encouraging efficacy signalsBOSTON…
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of…
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the…
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit…
The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients…
New Nonprofit Founded by Leading Testosterone Experts Seeks to Provide Equal Access to Care for Both Men and WomenRALEIGH, N.C.,…
Dr Mark Hawass Founder of Arthritis VIP LONDON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Dr. Mark Hawass, the trailblazing founder…
Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage DeterminationCANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE)…
LOUISVILLE, Ky., Nov. 15, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK) (the “Company”), a provider of personal emergency response systems…
Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV…